Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IL-2-driven CD8+ T cell phenotypes: implications for immunotherapy.

Trends in immunology - 1 Nov 2023

Niederlova Veronika, Tsyklauri Oksana, Kovar Marek, Stepanek Ondrej

Abstract excerpt

The therapeutic potential of interleukin (IL)-2 in cancer treatment has been known for decades, yet its widespread adoption in clinical practice remains limited. Recently, chimeric proteins of an anti-PD-1 antibody and suboptimal IL-2 variants were shown to stimulate potent antitumor and antiviral immunity by inducing unique effector CD8+ T cells in mice. A similar subset of cytotoxic T cells is induced by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to CD8-Positive T-Lymphocytes
Share to Immunotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interleukin-2

Share to Phenotype

Share to T-Lymphocytes, Cytotoxic

Share to T-Lymphocytes, Regulatory

Source

Open in PubMed Open full text

Identifiers

PMID: 37827864
DOI: 10.1016/j.it.2023.09.003
PMCID: PMC7615502

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IL-2-driven CD8+ T cell phenotypes: implications for immunotherapy.PMID 37827864Read ↗

Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical TherapiesSemantic proximity Read ↗

Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategiesSemantic proximity Read ↗

Differentiating PD-1+ stem-like CD8 T cells towards distinct effectors with enhanced therapeutic potential by an engineered IL-2 cis-targeted to PD-1Semantic proximity Read ↗

CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.Semantic proximity Read ↗

CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade.Semantic proximity Read ↗

Group 2 Innate Lymphoid Cells: A Double-Edged Sword in Cancer?Semantic proximity Read ↗

New therapeutic strategies based on biasing IL-2 mutants for cancers and autoimmune diseasesSemantic proximity Read ↗

Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?Semantic proximity Read ↗

Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma.Semantic proximity Read ↗

Human IL-2 mutein with higher antitumor efficacy than wild type IL-2.Semantic proximity Read ↗

Bridging therapy-induced phenotypes and genetic immune dysregulation to study interleukin-2-induced immunotoxicology.Semantic proximity Read ↗

PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.